Home›Duvelisib›Duvelisib + Sensitive Cyp3a Substrates

Does Duvelisib Interact with Sensitive Cyp3a Substrates?

CDI records a moderate classification for Duvelisib and Sensitive Cyp3a Substrates. The stored summary is: COPIKTRA increases AUC of sensitive CYP3A4 substrates, which may increase the risk of toxicities. Monitor for signs of toxicities and consider reducing substrate dose. The mechanism involves copiktra inhibits cyp3a4, increasing substrate exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity: Moderate
Management: Monitor for effects
Data Source: U.S. FDA via OpenFDA

Recorded Mechanism

COPIKTRA inhibits CYP3A4, increasing substrate exposure

What To Tell Your Doctor or Pharmacist

If you are taking Duvelisib and your doctor is considering prescribing Sensitive Cyp3a Substrates (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask whether any dosage adjustments are needed
Never stop or change either medication without first consulting your healthcare provider

💊 Duvelisib(Copiktra)+💊 Sensitive Cyp3a Substrates(Fluorimax Sensitive)

Severity & Interaction Details

🟡

moderate

Be aware — moderate interaction

Documented interaction with manageable risk. May require dose adjustment or monitoring.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

—

Source

NLP:duvelisib

What this means in plain English

COPIKTRA increases AUC of sensitive CYP3A4 substrates, which may increase the risk of toxicities. Monitor for signs of toxicities and consider reducing substrate dose.

About Duvelisib and Sensitive Cyp3a Substrates

Duvelisib is also sold under the brand name Copiktra. Duvelisib additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:duvelisib

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Duvelisib and Sensitive Cyp3a Substrates against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.